{{Short description|American health data analytics company}} {{Infobox company | name = Truveta, Inc. | logo = Truveta company logo.svg | type = Private | founded = 2020 | industry = Health technology | key_people = Terry Myerson, CEO | website = {{URL|https://www.truveta.com/}} | headquarters = Bellevue, Washington, U.S.A. }}
'''Truveta, Inc.''' is an American health data and analytics company headquartered in Bellevue, Washington and owned and governed by 30 U.S. health systems.<ref>{{cite news |date=2021-02-24 |title=Truveta data expands beyond EHR |url=https://finance.yahoo.com/news/truveta-data-expands-beyond-ehr-140000389.html |work=Yahoo Finance }}</ref>
'''Truveta''' was established in 2020 by Providence, Advocate Health, Tenet Healthcare, and Trinity Health. The company was publicly introduced in February 2021 with fourteen founding health system members.<ref name="auto1">{{cite news |last1=Boss |first1=Dina |last2=Tozzi |first2=John |date=2021-02-11 |title=Startup Truveta links U.S. health systems to share patient data |url=https://www.bloomberg.com/news/articles/2021-02-11/startup-truveta-links-u-s-health-systems-to-share-patient-data |work=Bloomberg }}</ref> As of 2025, Truveta includes 30 U.S. health systems as members.<ref name="healthcareitnews">{{cite news |last1=Fox |first1=Andrea |title=Truveta and 30 health systems increase genomic sequencing goal |url=https://www.healthcareitnews.com/news/truveta-and-30-health-systems-increase-genomic-sequencing-goal |access-date=11 December 2025 |work=Healthcare IT News |date=15 January 2025}}</ref> Truveta provides de-identified electronic health record data for more than 120 million U.S. patients.<ref name="healthcareitnews"/><ref name="auto1"/>
==History== Truveta was formed in September 2020 by a group of U.S. health systems seeking to develop a shared data resource.<ref>{{cite news | last=Mathews | first=Anna Wilde | title=Major Hospitals Form Company to Capitalize on Their Troves of Health Data | url=https://www.wsj.com/health/healthcare/major-hospitals-form-company-to-capitalize-on-their-troves-of-health-data-11613052000 | work=The Wall Street Journal | date=2021-02-11 | access-date=2025-12-03 }}</ref> The company was publicly introduced in February 2021, with initial participating systems including AdventHealth, Advocate Aurora Health, Baptist Health of Northeast Florida, Bon Secours Mercy Health, CommonSpirit Health, Hawaii Pacific Health, Henry Ford Health System, Memorial Hermann Health System, Northwell Health, Novant Health, Providence, Sentara Healthcare, Tenet Health, and Trinity Health.<ref name="auto1"/>
In 2021, Truveta entered a partnership with Microsoft to support its cloud and artificial intelligence infrastructure.<ref>{{cite news | last=Miliard | first=Mike | title=Truveta, Microsoft form cloud AI partnership with strategic investment | url=https://www.healthcareitnews.com/news/truveta-microsoft-form-cloud-ai-partnership-strategic-investment | work=Healthcare IT News | date=2021-09-30 | access-date=2025-12-03 }}</ref> Later that year, the company released its first data platform and shared initial analytic findings.<ref>{{cite news | last=Schubert | first=Charlotte | title=Healthcare-data startup Truveta showcases new platform, now raised close to $200M | url=https://www.geekwire.com/2021/healthcare-data-startup-truveta-showcases-new-platform-now-raised-close-200m/ | work=GeekWire | date=2021-10-11 | access-date=2025-12-03 }}</ref>
In 2022, Pfizer became Truveta's first life sciences customer,<ref>{{cite news | last=Wu | first=Lei Lei | title=Big data meets Big Pharma: Pfizer buys real-time patient results in collaboration with Truveta | url=https://endpoints.news/big-data-meets-big-pharma-pfizer-buys-real-time-patient-results-in-collaboration-with-truveta/ | work=Endpoints News | date=2022-06-21 | access-date=2025-12-03 }}</ref><ref>{{cite news | last=Schubert | first=Charlotte | title=Health data company Truveta to partner with Pfizer on monitoring COVID vaccines and therapies | url=https://www.geekwire.com/2022/health-data-company-truveta-to-partner-with-pfizer-on-monitoring-covid-vaccines-and-therapies/ | work=GeekWire | date=2022-06-21 | access-date=2025-12-03 }}</ref> and Boston Scientific also began using the company's data platform.<ref>{{cite news | last=Diller | first=Wendy | title=Truveta and Boston Scientific Strive for the Ultimate in Data Sharing: Speed, Accuracy, and Privacy | url=https://www.mystrategist.com/medtech-strategist/article/truveta_and_boston_scientific_strive_for_the_ultimate_in_data_sharing_speed_accuracy_and_privacy.html | work=MedTech Strategist | date=2022-11-17 | access-date=2025-12-03 }}</ref> In 2023, Truveta introduced the Truveta Language Model, a multimodal large-language model designed to structure clinical data from electronic health records.<ref>{{cite web | last = Lampton | first = Ellie | title = Announcing the Truveta Language Model | url = https://www.truveta.com/blog/announcement/truveta-language-model | website = Truveta | date = 2023-04-12 | access-date = 2025-12-03 }}</ref><ref>{{cite news | last = Schubert | first = Charlotte | title = This AI understands doctors' notes: Truveta's new model finds meaning in messy healthcare data | url = https://www.geekwire.com/2023/this-ai-understands-doctors-notes-truvetas-new-model-finds-meaning-in-messy-healthcare-data/ | work = GeekWire | date = 2023-04-13 | access-date = 2025-12-03 }}</ref> In 2025, the company launched the Truveta Genome Project in collaboration with participating health systems, Regeneron, Illumina, and Microsoft, alongside raising $320 million in Series C funding.<ref>{{cite web | last = Leake | first = Lindsey | title = Truveta genome project teams with Regeneron and Illumina to sequence US health-system patients | url = https://fortune.com/well/article/truveta-genome-project-regeneron-illumina/ | website = Fortune | date = 2025-01-16 | access-date = 2025-12-03 }}</ref><ref>{{cite news | last = Niasse | first = Amina | title = Truveta sells stakes in Regeneron-Illumina deal to help build genetic database | url = https://www.reuters.com/markets/deals/truveta-sells-stakes-regeneron-illumina-deal-build-genetic-database-2025-01-13/ | work = Reuters | date = 2025-01-13 | access-date = 2025-12-03 }}</ref>
== Research using Truveta data == Studies using Truveta data have been published in peer-reviewed journals across infectious diseases, cardiology, pediatrics, gastroenterology, medical informatics, health services research, and population health.
=== Infectious diseases and public health === A 2023 study published in ''Vaccine'' assessed the risk of COVID-19 breakthrough infection and hospitalization among individuals with comorbidities using data from U.S. health-system records, including those from Truveta-affiliated systems.<ref>{{cite journal | last1 = Smits | first1 = Peter D. | last2 = Gratzl | first2 = Samuel | last3 = Simonov | first3 = Michael | last4 = Nachimuthu | first4 = Senthil K. | last5 = Goodwin Cartwright | first5 = Brianna M. | last6 = Wang | first6 = Michael D. | last7 = Baker | first7 = Charlotte | last8 = Rodriguez | first8 = Patricia | last9 = Bogiages | first9 = Mackenzie | last10 = Althouse | first10 = Benjamin M. | last11 = Stucky | first11 = Nicholas L. | title = Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities | journal = Vaccine | date = 2023-03-29 | volume = 41 | issue = 15 | pages = 2447–2455 | doi = 10.1016/j.vaccine.2023.02.038 | pmid = 36803895 | pmc = 9933320 }}</ref> A 2023 study in ''Frontiers in Public Health'' evaluated racial inequalities in COVID-19 treatment and in-hospital length of stay in the United States over time, using data derived from large health-system datasets including those affiliated with Truveta.<ref>{{cite journal | last1 = Althouse | first1 = Benjamin M. | last2 = Baker | first2 = Charlotte | last3 = Smits | first3 = Peter D. | last4 = Gratz | first4 = Samuel | last5 = Lee | first5 = Ryan H. | last6 = Goodwin Cartwright | first6 = Brianna M. | last7 = Simonov | first7 = Michael | last8 = Wang | first8 = Michael D. | last9 = Stucky | first9 = Nicholas L. | title = Racial inequality in COVID-treatment and in-hospital length of stay in the US over time | journal = Frontiers in Public Health | date = 2023-01-10 | volume = 10 | article-number = 1074775 | doi = 10.3389/fpubh.2022.1074775 | pmid = 36711416 | pmc = 9876573 | bibcode = 2023FrPH...1074775A | doi-access = free }}</ref> A 2025 study published in the ''American Journal of Preventive Medicine'' analyzed trends in syphilis incidence among U.S. adults from January 2017 to October 2024 using Truveta data.<ref>{{cite journal | last1 = Do | first1 = Duy | last2 = Rodriguez | first2 = Patricia J. | last3 = Gratzl | first3 = Samuel | last4 = Goodwin Cartwright | first4 = Brianna M. | last5 = Baker | first5 = Charlotte | last6 = Stucky | first6 = Nicholas L. | title = Trends in Incidence of Syphilis Among US Adults from January 2017 to October 2024 | journal = American Journal of Preventive Medicine | date = 2025-04-01 | doi = 10.1016/j.amepre.2025.03.008 | pmid = 40185421 | url = https://www.ajpmonline.org/article/S0749-3797(25)00106-0/fulltext | access-date = 2025-12-03 }}</ref> Another 2025 study in ''Sexually Transmitted Diseases'' assessed the need for creating ICD-10 codes to improve monitoring of doxycycline postexposure prophylaxis prescriptions in the United States.<ref>{{cite journal | last1 = Tao | first1 = Guoyu | last2 = He | first2 = Larry | last3 = Patel | first3 = Chirag | last4 = Papp | first4 = John | last5 = Barbee | first5 = Lindley A. | title = Assessing the need for creating ICD-10 codes to enhance monitoring of doxycycline postexposure prophylaxis prescriptions in the United States | journal = Sexually Transmitted Diseases | date = 2025-09-18 | volume = 53 | issue = 2 | pages = 93–96 | doi = 10.1097/OLQ.0000000000002245 | pmid = 40965055 | url = https://journals.lww.com/stdjournal/abstract/9900/assessing_the_need_for_creating_icd_10_codes_to.572.aspx | access-date = 2025-12-03 | url-access = subscription }}</ref>
=== Cardiology and cardiovascular outcomes === Truveta data have been used in several cardiovascular studies. A real-world, big-data analysis in the ''Journal of the Society for Cardiovascular Angiography & Interventions''<ref>{{Cite web|url=https://www.jscai.org/|title=Home Page: Journal of the Society for Cardiovascular Angiography & Interventions|website=www.jscai.org|accessdate=Dec 9, 2025}}</ref> compared ultrasound-assisted catheter-directed therapy (USCDT) with medical therapy for pulmonary embolism (the REAL-PE study), based on data drawn from Truveta-affiliated health systems.<ref>{{cite journal | last1 = Monteleone | first1 = Peter | last2 = Ahern | first2 = Ryan A. | last3 = Banerjee | first3 = Subhash | last4 = Desai | first4 = Kush R. | last5 = Kadian-Dodov | first5 = Daniella | last6 = Webber | first6 = Emily | last7 = Omidvar | first7 = Sally | last8 = Troy | first8 = Patrick | last9 = Parikh | first9 = Sahil A. | title = Modern Treatment of Pulmonary Embolism (USCDT vs MT): Results From a Real-World, Big Data Analysis (REAL-PE) | journal = Journal of the Society for Cardiovascular Angiography & Interventions | date = 2023-10-24 | volume = 3 | issue = 1 | article-number = 101192 | doi = 10.1016/j.jscai.2023.101192 | pmid = 39131982 | pmc = 11308131 | url = https://www.jscai.org/article/S2772-9303(23)01194-8/fulltext | access-date = 2025-12-03 }}</ref> A subsequent 2024 analysis in the same journal reported additional real-world findings on USCDT versus standard medical therapy for pulmonary embolism using U.S. health-system records, including those from Truveta-affiliated systems.<ref>{{cite journal | last1 = Monteleone | first1 = Peter | last2 = Ahern | first2 = Ryan A. | last3 = Banerjee | first3 = Subhash | last4 = Desai | first4 = Kush R. | last5 = Kadian-Dodov | first5 = Daniella | last6 = Webber | first6 = Emily | last7 = Omidvar | first7 = Sally | last8 = Troy | first8 = Patrick | last9 = Parikh | first9 = Sahil A. | title = Modern Treatment of Pulmonary Embolism (USCDT vs MT): Results From a Real-World, Big Data Analysis (REAL-PE) | journal = Journal of the Society for Cardiovascular Angiography & Interventions | date = 2024-01-01 | volume = 3 | issue = 1 | article-number = 101192 | doi = 10.1016/j.jscai.2023.101192 | pmid = 39131982 | url = https://www.jscai.org/article/S2772-9303(23)01194-8/fulltext | access-date = 2025-12-03 | pmc = 11308131 }}</ref> A 2024 cohort study in ''JACC: Heart Failure'' evaluated decongestion strategies in patients hospitalized for heart failure using a large community-based dataset including records from Truveta-affiliated health systems.<ref>{{cite journal | last1 = Zheng | first1 = Jimmy | last2 = Ambrosy | first2 = Andrew P. | last3 = Bhatt | first3 = Ankeet S. | last4 = Collins | first4 = Sean P. | last5 = Flint | first5 = Kelsey M. | last6 = Fonarow | first6 = Gregg C. | last7 = Fudim | first7 = Marat | last8 = Greene | first8 = Stephen J. | last9 = Lala | first9 = Anuradha | last10 = Testani | first10 = Jeffrey M. | last11 = Varshney | first11 = Anubodh S. | last12 = Wi | first12 = Ryan S.K. | last13 = Sandhu | first13 = Alexander T. | title = Contemporary Decongestion Strategies in Patients Hospitalized for Heart Failure: A National Community-Based Cohort Study | journal = JACC: Heart Failure | date = 2024-04-07 | volume = 12 | issue = 8 | pages = 1381–1392 | doi = 10.1016/j.jchf.2024.04.002 | pmid = 38678466 | url = https://www.jacc.org/doi/10.1016/j.jchf.2024.04.002 | access-date = 2025-12-03 }}</ref> In 2025, a real-world analysis in the ''Journal of Cardiac Failure'' evaluated survival outcomes associated with cardiac contractility modulation devices, using cardiac resynchronization therapy data to validate methodological approaches with large U.S. health-system records, including those from Truveta-affiliated systems.<ref>{{cite journal | last1 = Sauer | first1 = Andrew J. | last2 = Hass | first2 = Ryan | last3 = Cranke | first3 = Gary | last4 = Burkhoff | first4 = Daniel | last5 = Rao | first5 = Ishu | title = Real-World Survival Outcomes With Cardiac Contractility Modulation: Methodological Validation Using Cardiac Resynchronization Therapy Data | journal = Journal of Cardiac Failure | volume = 31 | issue = 9 | pages = 1490–1492 | date = 2025-09-01 | url = https://onlinejcf.com/article/S1071-9164(25)00232-5/fulltext | doi = 10.1016/j.cardfail.2025.08.009 | pmid = 41233031 | pmc = 12661499 | pmc-embargo-date = 2026-11-01 | access-date = 2025-12-03 }}</ref>
=== Pediatrics === In pediatrics, a 2023 time-series study published in ''JAMA Pediatrics'' examined first-time pediatric speech delay incidence from 2018 to 2022 using data from U.S. health systems, including those affiliated with Truveta.<ref>{{cite journal | last1 = Goodwin Cartwright | first1 = Brianna M. | last2 = Smits | first2 = Peter D. | last3 = Stewart | first3 = Sarah | title = Time-Series Analysis of First-Time Pediatric Speech Delays From 2018 to 2022 | journal = JAMA Pediatrics | date = 2023-12-04 | volume = 178 | issue = 2 | pages = 193–195 | doi = 10.1001/jamapediatrics.2023.5226 | pmid = 38048098 | pmc = 10696512 }}</ref> A 2025 study in ''Pediatrics Open Science'' examined changes in pediatric obesity treatment practices in the United States following updated guidelines from the American Academy of Pediatrics, using data from large health-system records, including those affiliated with Truveta.<ref>{{cite journal | last1 = Rodriguez | first1 = Patricia J. | last2 = Do | first2 = Duy | last3 = Gratzl | first3 = Samuel | last4 = Goodwin-Cartwright | first4 = Brianna M. | last5 = Stucky | first5 = Nicholas L. | last6 = Wright | first6 = Davene R. | title = Shifts in US Pediatric Obesity Treatment After the AAP Guidelines | journal = Pediatrics Open Science | date = 2025-08-01 | volume = 1 | issue = 3 | pages = 1–12 | doi = 10.1542/pedsos.2025-000623 | doi-access = free }}</ref>
=== Pharmacoepidemiology and therapeutics === A 2023 study in ''JAMA Network Open'' examined changes in prescribing patterns of oral minoxidil for hair loss after media attention, using prescription data from U.S. health-system records, including those affiliated with Truveta.<ref>{{cite journal | last1 = Goodwin Cartwright | first1 = Brianna M. | last2 = Wang | first2 = Michael | last3 = Rodriguez | first3 = Patricia | last4 = Stewart | first4 = Sarah | last5 = Worsham | first5 = Christopher M. | last6 = Stucky | first6 = Nick | last7 = Jena | first7 = Anupam B. | title = Changes in Minoxidil Prescribing After Media Attention About Oral Use for Hair Loss | journal = JAMA Network Open | date = 2023-05-09 | volume = 6 | issue = 5 | pages = e2312477 | doi = 10.1001/jamanetworkopen.2023.12477 | pmid = 37159202 | pmc = 10170338 }}</ref> A 2025 study, also in ''JAMA Network Open'', examined patterns of discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among U.S. adults with overweight or obesity using Truveta data.<ref>{{cite journal | last1 = Rodriguez | first1 = Patricia J. | last2 = Zhang | first2 = Vincent | last3 = Gratzl | first3 = Samuel | title = Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity | journal = JAMA Network Open | date = 2025-01-31 | volume = 8 | issue = 1 | pages = e2457349 | doi = 10.1001/jamanetworkopen.2024.57349 | pmid = 39888616 | pmc = 11786232 }}</ref> In 2024, a study in ''JAMA Internal Medicine'' compared the effectiveness of semaglutide versus tirzepatide for weight loss in adults with overweight or obesity, using data from Truveta-affiliated health systems.<ref>{{cite journal | last1 = Rodriguez | first1 = Patricia J. | last2 = Goodwin Cartwright | first2 = Brianna M. | last3 = Gratzl | first3 = Samuel | title = Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity | journal = JAMA Internal Medicine | date = 2024-07-08 | volume = 184 | issue = 9 | pages = 1056–1064 | doi = 10.1001/jamainternmed.2024.2525 | pmid = 38976257 | pmc = 11231910 }}</ref>
=== Gastroenterology and cancer screening === A 2024 study published in ''The American Journal of Gastroenterology'' examined real-world adherence to repeat stool-based colorectal cancer screening among individuals at average risk, using fecal immunochemical tests (FIT) and multi-target stool DNA tests (mt-sDNA). The authors analyzed patterns of repeat testing and evaluated factors associated with adherence over time.<ref>{{cite journal | last1 = Shaukat | first1 = Aasma | last2 = Liao | first2 = Jiemin | last3 = Saha | first3 = Jayati | last4 = Forbes | first4 = Shaun P. | last5 = Watkins | first5 = Angela | last6 = Zhang | first6 = Nicole J. | last7 = Raymond | first7 = Victoria M. | last8 = Das | first8 = Amarendra | last9 = Eagle | first9 = Craig | last10 = Talasaz | first10 = AmirAli | title = S375 Real-World Adherence to Repeat Testing for Stool-Based Non-Invasive Colorectal Cancer Screening Tests Among Individuals With Average Risk | journal = The American Journal of Gastroenterology | volume = 119 | issue = 10S | pages = S265–S266 | date = 2024-10-01 | doi = 10.14309/01.ajg.0001030868.43296.05 | url = https://journals.lww.com/ajg/fulltext/2024/10001/s375_real_world_adherence_to_repeat_testing_for.376.aspx | access-date = 2025-12-03 | url-access = subscription }}</ref>
=== Nephrology and procedural outcomes === A 2025 retrospective evaluation in ''The International Journal of Artificial Organs'' analyzed design features, associated risks, and usage trends of non-tunneled hemodialysis catheters, comparing dual- and triple-lumen devices based on real-world data.<ref>{{cite journal | last1 = Miller | first1 = George | last2 = Zabaleta | first2 = Isabella | last3 = Ogujiofor | first3 = Kingsley | last4 = Fatima | first4 = Rukhaiya | last5 = Albrecht | first5 = Emma | last6 = Warden | first6 = Madalyn | title = Design features, associated risks, and usage trends of non-tunneled hemodialysis catheters: A retrospective evaluation of dual and triple lumen devices | date = 2025-07-02 | doi = 10.1177/11297298251352470 | pmid = 40605326 | journal = The International Journal of Artificial Organs }}</ref> Another 2025 study, published in ''Journal of Endourology / Urology & Nephrology Clinics'', compared postoperative infection rates for patients using a single-use ureteroscope with real-time intrarenal pressure monitoring versus other single-use ureteroscopes in clinical practice, using large health-system datasets.<ref>{{cite journal | last1 = Bhojani | first1 = Naeem | last2 = Morris | first2 = Kathryn | last3 = White | first3 = Jenifer | last4 = Rojanasarot | first4 = Sirikan | last5 = Tran | first5 = Emma D. | last6 = Monga | first6 = Manoj | title = Post-operative infection with a single-use ureteroscope with real-time intrarenal pressure monitoring vs. all other single-use ureteroscopes | journal = Journal of Endourology / Urology & Nephrology Clinics | date = 2025-09-16 | volume = 22 | issue = 10 | pages = 1135–1143 | doi = 10.1080/17434440.2025.2557403 | pmid = 40908713 | url = https://www.tandfonline.com/doi/full/10.1080/17434440.2025.2557403 | access-date = 2025-12-03 | url-access = subscription }}</ref>
=== Medical informatics, AI, and multimodal modeling === Several studies have focused on data standards and artificial intelligence using Truveta data. A 2023 preprint titled ''Truveta Mapper: A Zero-shot Ontology Alignment Framework'' presented a methodology for aligning biomedical ontologies using zero-shot learning, as a tool that could support data interoperability for health systems.<ref>{{cite arXiv | last1 = Amir | first1 = Mariyam | last2 = Baruah | first2 = Murchana | last3 = Eslamialishah | first3 = Mahsa | last4 = Ehsani | first4 = Sina | last5 = Bahramali | first5 = Alireza | last6 = Naddaf-sh | first6 = Sadra | last7 = Zarandioon | first7 = Saman | title = Truveta Mapper: A Zero-shot Ontology Alignment Framework | date = 2023-01-24 | class = cs.LG | eprint = 2301.09767 }}</ref> A 2025 study published in ''Studies in Health Technology and Informatics'' explored structured large language model (LLM) augmentation for clinical information extraction, assessing its performance and potential for healthcare data analysis.<ref>{{cite journal | last1 = Wei | first1 = Ying | last2 = Li | first2 = Qi | last3 = Pillai | first3 = Jay | title = Structured LLM Augmentation for Clinical Information Extraction | journal = Studies in Health Technology and Informatics | date = 2025-08-07 | volume = 329 | pages = 971–976 | doi = 10.3233/SHTI250984 | pmid = 40776002 | isbn = 978-1-64368-608-0 | doi-access = free }}</ref> In 2025, a study in ''Radiology Advances'' developed "XComposition", a multimodal deep-learning model that uses chest radiographs and clinical data to estimate body composition, as an application of large health-system data for medical imaging research.<ref>{{cite journal | last1 = Alipour | first1 = Ehsan | last2 = Gratzl | first2 = Samuel | last3 = Algohary | first3 = Ahmad | last4 = Lin | first4 = Hao | last5 = Bapat | first5 = Manoj | last6 = Do | first6 = Duy | last7 = Baker | first7 = Charlotte | last8 = Rodriguez | first8 = Tricia | last9 = Goodwin Cartwright | first9 = Brianna M. | last10 = Hadlock | first10 = Jennifer | last11 = Tarczy-Hornoch | first11 = Peter | last12 = Oka | first12 = Anand | last13 = Stucky | first13 = Nicholas L. | title = XComposition: multimodal deep learning model to measure body composition using chest radiographs and clinical data | journal = Radiology Advances | date = 2025-10-03 | volume = 2 | issue = 5 | article-number = umaf035 | doi = 10.1093/radadv/umaf035 | pmid = 41164313 | pmc = 12560821 | url = https://academic.oup.com/radadv/article/2/5/umaf035/8272835 | access-date = 2025-12-03 }}</ref>
== References ==
{{reflist}}
Category:2020 establishments in Washington (state) Category:American companies established in 2020 Category:Companies based in Bellevue, Washington Category:Health care companies established in 2020